Arvanitis, LA, Miller, BG.
Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry
1997; 42: 233–46.
Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M.
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology
1999; 20: 491–505.
Kane, JM, Woerner, M, Lieberman, J.
Prevalence, incidence, and risk factors. J Clin Psychopharmacol
1988; 8 (suppl): 52–6.
Marder, SR, Meibach, RC.
Risperidone in the treatment of schizophrenia. Am J Psychiatry
1994; 151: 825–35.
Potkin, SG, Saha, AR, Kujawa, MJ, Carson, WH, Ali, M, Stock, E, et al.
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry
2003; 60: 681–90.
Tollefson, GD, Sanger, TM.
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry
1997; 154: 466–74.
Gebhardt, S, Hartling, F, Hanke, M, Mittendorf, M, Theisen, FM, Wolf-Ostermann, K, et al.
Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry
2006; 15: 371–82.
Caroff, SN, Mann, SC, Campbell, EC, Sullivan, KA.
Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry
2002; 63 (suppl 4): 12–9.
Conner, DE, Fletcher, KE, Wood, JS.
Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry
2001; 62: 967–74.
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Psychiatry
2000; 61: 16–21.
Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry
2004; 65 (suppl 9): 16–20.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al.
Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, et al.
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA
2003; 290: 2693–702.
Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W.
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet
2003; 361: 1581–9.
Rochon, PA, Stukel, TA, Sykora, K, Gill, S, Garfinkel, S, Anderson, GM, et al.
Atypical antipsychotics and parkinsonism. Arch Intern Med
2006; 165: 1882–8.
Second generation antipsychotics. Psychopharmacology (Berl)
2002; 162: 90–1.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol
2011; 25: 567–620.
Verdoux, H, Tournier, M, Bégaud, B.
Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand
2010; 121: 4–10.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Miller, DD, Caroff, SN, Davis, SM, Rosenheck, RA, McEvoy, JP, Saltz, BL, et al.
Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry
2008; 193: 279–88.
Hugenholtz, GW, Heerdink, ER, Stolker, JJ, Meijer, WE, Egberts, AC, Nolen, WA.
Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry
2006; 67: 897–903.
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P.
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ
2000; 32: 1371–6.
Lewis, SW, Davies, L, Jones, PB, Barnes, TRE, Murray, RM, Kerwin, R, et al.
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess
2006; 10: 1–83.
Henrichs, DW, Hanlon, TE, Carpenter, WT.
The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull
1984; 10: 388–98.
The Barnes Akathisia Rating Scale: revisited. J Psychopharmacol
2003; 17: 365–70.
Simpson, G, Angus, JSW.
A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl
1970; 212: 9–11.
ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.
A Dictionary of Epidemiology (4th edn). Oxford University Press, 2001.
Klawans, HL, Rubovits, R.
Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry
1974; 37: 941–7.
Greil, W, Haag, H, Rossnagl, G, Rüther, E.
Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry
1984; 145: 304–10.
Moore, NA, Tye, NC, Axton, MS, Risius, FC.
The behavioral pharmacology of olanzapine, a novel ‘atypical’ antipsychotic agent. J Pharmacol Exp Ther
1992; 262: 545–51.
Lloyd, HM, Markwick, AJ, Page, ER, Lewis, S, Barnes, TRE.
Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the CUtLASS study. Int J Psychiatry Clin Pract
2005; 9: 35–40.
Ren, XS, Huang, YH, Lee, AF, Miller, DR, Qian, S, Kazis, L.
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther
2005; 30: 65–71.
Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv
2005; 56: 85–92.
Cheng, F, Jones, PB.
Second-generation atypical versus first-generation conventional antipsychotic drug treatment in schizophrenia: another triumph of hope over experience? In Therapeutic Strategies in Schizophrenia (eds Mortimer, A, McKenna, PJ): 193–206. Clinical Publishing, 2010.
Mackin, P, Thomas, SH.
Atypical antipsychotic drugs. BMJ
2011; 342: d1126.